Destruction of conditional insulinoma cell lines in NOD mice: a role for autoimmunity.
OBJECTIVE
betaTC-tet (H2(k)) is a conditional insulinoma cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Transgenic expression of several proteins implicated in the apoptotic pathways increase the resistance of betaTC-tet cells in vitro. We tested in vivo the sensitivity of the cells to rejection and the protective effect of genetic alterations in NOD mice.


METHODS
betaTC-tet cells and genetically engineered lines expressing Bcl-2 (CDM3D), a dominant negative mutant of MyD88 or SOCS-1 were transplanted in diabetic female NOD mice or in male NOD mice with diabetes induced by high-dose streptozotocin. Survival of functional cell grafts in NOD-scid mice was also analyzed after transfer of splenocytes from diabetic NOD mice. Autoreactive T-cell hybridomas and splenocytes from diabetic NOD mice were stimulated by betaTC-tet cells.


RESULTS
betaTC-tet cells and genetically engineered cell lines were all similarly rejected in diabetic NOD mice and in NOD-scid mice after splenocyte transfer. In 3- to 6-week-old male NOD mice treated with high-dose streptozotocin, the cells temporarily survived, in contrast with C57BL/6 mice treated with high-dose streptozotocin (indefinite survival) and untreated 3- to 6-week-old male NOD mice (rejection). The protective effect of high-dose streptozotocin was lost in older male NOD mice. betaTC-tet cells did not stimulate autoreactive T-cell hybridomas, but induced IL-2 secretion by splenocytes from diabetic NOD mice.


CONCLUSIONS
The autoimmune process seems to play an important role in the destruction of betaTC-tet cells in NOD mice. Genetic manipulations intended at increasing the resistance of beta cells were inefficient. Similar approaches should be tested in vivo as well as in vitro. High dose streptozotocin influences immune rejection and should be used with caution.
INSERM U561, Groupe hospitalier Cochin-Saint Vincent de Paul, Paris, France.
P
P
Cattan
D
D
Rottembourg
S
S
Cottet
I
I
Tardivel
P
P
Dupraz
B
B
Thorens
C
C
Boitard
J C
JC
Carel
D000818:Animals; D015551:Autoimmunity / Q000276:immunology*; D045744:Cell Line, Tumor; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000378:metabolism; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006825:Hybridomas / Q000378:metabolism; D007340:Insulinoma / Q000276:immunology* / Q000378:metabolism; D007376:Interleukin-2 / Q000493:pharmacokinetics; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD / Q000276:immunology*; D013154:Spleen / Q000378:metabolism; D019737:Transplants
D007376:Interleukin-2